Submit Content Become a member
Colin Hay

Cervical cancer screening test specialist TruScreen Group (ASX: TRU) has appointed Indonesian medical products distributor PT Mawar Mitra Medika to distribute its unique AI enabled TruScreen system in Indonesia.

Indonesia, with a population exceeding 283 million, is the world’s most populous Islamic nation. It has an addressable screening market of 95 million women. It is estimated that around 37,000 women are diagnosed with and 21,000 die from cervical cancer each year in Indonesia yet only 11% of women have ever been screened for cervical cancer.

With over 14,000 islands in the Indonesian archipelago TruScreen’s portability and its AI enabled technology provides real time results without the needs of expensive laboratory infrastructure, makes it an ideal screening solution for such a geographically distributed population. TruScreen technology is non-invasive and is culturally sensitive to Indonesian patients as it does not require a collection of cervical cells.

The appointment follows the registration of TruScreen by the Indonesian regulator in October 2024. In December 2024, TruScreen CEO, Martin Dillon met with Indonesian Key Opinion Leaders and Ministry of Health Officials to explore the use of AI technology to reduce the unnecessary loss of life from cervical cancer.

TruScreen acknowledges the assistance of Austrade Jakarta, for facilitating the appointment of PT Mawar Mitra Medika.

Mr Dillon was invited to present at the Indonesian AI webinar, subsequent to his participation in a November 2024 WHO meeting, in Edinburgh, to explore the use of AI enabled devices for the screening of cervical cancer. TruScreen was recognised by WHO, UNITAID and several national organisations including:

  • the Chinese Obstetricians and Gynaecologists Association (COGA),
  • the Chinese Society for Colposcopy and Cervical Pathology (CSCCP),
  • the Vietnam Ministry of Health National Technical List,
  • COFEPRIS, the Mexican public health regulator, and
  • The Russia Cervical Cancer Screening Guidelines.

TruScreen CEO, Martin Dillon commented:

“This appointment supports two key strategies of TruScreen. The first is to complete a vertical East Asian distribution focus from Indonesia, north through the ASEAN countries, Vietnam and Indo- China and then China. This regional vertical market is now in place. The second is a focus on Asia’s populous Islamic nations. Our Indonesian distributor complements our distributors in Saudi Arabia, UAE, Kuwait, Jordan and Palestine,” Mr Dillon said.

Rate article from Colin Hay: